These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33341481)

  • 21. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
    Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
    Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
    Gates LE; Hamed AA
    J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
    Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
    Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
    Alsharif MH; Alsharif YH; Albreem MA; Jahid A; Solyman AAA; Yahya K; Alomari OA; Hossain MS
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11977-11981. PubMed ID: 33275275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.
    Malik P; Jain S; Jain P; Kumawat J; Dwivedi J; Kishore D
    Arch Pharm (Weinheim); 2022 May; 355(5):e2100382. PubMed ID: 35040187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.
    Wang Y; Chen L
    Eur J Pharmacol; 2020 Dec; 889():173634. PubMed ID: 33031797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
    Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
    Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
    Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
    Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
    Rodgers F; Pepperrell T; Keestra S; Pilkington V
    Trials; 2021 Jan; 22(1):59. PubMed ID: 33451350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
    Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
    Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports.
    Enyeji AM; Arora A; Mangat HS
    Viral Immunol; 2024 Aug; 37(6):298-307. PubMed ID: 39096169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Update on Current Therapeutic Drugs Treating COVID-19.
    Wu R; Wang L; Kuo HD; Shannar A; Peter R; Chou PJ; Li S; Hudlikar R; Liu X; Liu Z; Poiani GJ; Amorosa L; Brunetti L; Kong AN
    Curr Pharmacol Rep; 2020; 6(3):56-70. PubMed ID: 32395418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.